AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) – Investment analysts at B. Riley issued their Q1 2019 earnings estimates for shares of AVEO Pharmaceuticals in a research report issued to clients and investors on Tuesday. B. Riley analyst M. Kumar expects that the biopharmaceutical company will post earnings of ($0.05) per share for the quarter. B. Riley currently has a “Buy” rating and a $5.00 target price on the stock. B. Riley also issued estimates for AVEO Pharmaceuticals’ Q2 2019 earnings at ($0.05) EPS, Q3 2019 earnings at ($0.04) EPS, Q4 2019 earnings at ($0.04) EPS, FY2020 earnings at $0.02 EPS and FY2022 earnings at $0.23 EPS.
A number of other equities research analysts have also weighed in on AVEO. BidaskClub lowered shares of AVEO Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Tuesday, January 9th. Zacks Investment Research raised shares of AVEO Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, January 9th. Finally, began coverage on shares of AVEO Pharmaceuticals in a research report on Wednesday, November 15th. They set a “buy” rating and a $5.00 price objective for the company. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $4.05.
Hedge funds have recently modified their holdings of the company. Vanguard Group Inc. grew its position in shares of AVEO Pharmaceuticals by 48.6% during the 2nd quarter. Vanguard Group Inc. now owns 3,551,360 shares of the biopharmaceutical company’s stock valued at $7,884,000 after acquiring an additional 1,162,232 shares during the period. Emory University bought a new position in AVEO Pharmaceuticals in the 4th quarter worth $1,682,000. Essex Investment Management Co. LLC boosted its holdings in AVEO Pharmaceuticals by 34.1% in the 4th quarter. Essex Investment Management Co. LLC now owns 202,004 shares of the biopharmaceutical company’s stock worth $564,000 after buying an additional 51,384 shares during the period. X Square Capital LLC bought a new position in AVEO Pharmaceuticals in the 4th quarter worth $557,000. Finally, Prosight Management LP bought a new position in AVEO Pharmaceuticals in the 4th quarter worth $2,951,000. 51.82% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: This story was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this story on another site, it was stolen and reposted in violation of United States and international trademark & copyright law. The original version of this story can be viewed at https://www.americanbankingnews.com/2018/03/14/aveo-pharmaceuticals-inc-forecasted-to-earn-q1-2019-earnings-of-0-05-per-share-aveo.html.
AVEO Pharmaceuticals Company Profile
AVEO Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s platform delivers insights into cancer and related disease. The Company’s product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors.
Receive News & Ratings for AVEO Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.